Get the Stockscreener App
0.32
4.58%
0.014
Pre-market:
.32
Intensity Therapeutics Inc stock is traded at $0.32, with a volume of 5.65M.
It is up +4.58% in the last 24 hours and down -0.90% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.306
Open:
$0.3038
24h Volume:
5.65M
Relative Volume:
5.93
Market Cap:
$9.25M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.2709
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+15.52%
1M Performance:
-0.90%
6M Performance:
-83.76%
1Y Performance:
-93.50%
1-Day Range:
$0.2602
$0.35
1-Week Range:
$0.2602
$0.35
52-Week Range:
$0.2602
$5.10
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.32 | 9.25M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - The Globe and Mail
Why Is Intensity Therapeutics Stock (INTS) Down 50% Today? - The Globe and Mail
Intensity Therapeutics Completes $1.9 Million Stock Offering - TipRanks
Intensity Therapeutics Stock Falls 44% Today Should You Buy the Dip or Stay Away - thekhabrilal
Intensify Therapeutics slumps 27%, prices $2M stock offering - MSN
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - mx.advfn.com
Intensity Therapeutics (INTS) Shares Dive 27% Following Public O - GuruFocus
Intensity Therapeutics shares plummet on proposed public offering - MSN
ThinkEquity Leads Offering for INTS | INTS Stock News - GuruFocus
Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share - MarketScreener
Intensity Therapeutics, Inc. Announces Pricing of Public Offering - The Victoria Advocate
INTS: Intensity Therapeutics Reports Promising Results from Phas - GuruFocus
Intensity Therapeutics announces public offering of common stock By Investing.com - Investing.com India
Intensity Therapeutics (INTS) Announces Public Offering to Support Clinical Studies | INTS Stock News - GuruFocus
Intensity Therapeutics announces common stock offering, no amount given - TipRanks
Intensity Therapeutics announces public offering of common stock - Investing.com
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - StreetInsider
SEC Form 424B5 filed by Intensity Therapeutics Inc. - Quantisnow
Intensity Therapeutics Inc (INTS) Stock: A Year of Stock Market Dynamics - investchronicle.com
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCI - StreetInsider
Korn Ferry Sets Fiscal Year-End Earnings Release Date: Key Q4 Results Coming June 18 - Stock Titan
Intensity’s cancer drug shows tumor necrosis in early-stage study By Investing.com - Investing.com Nigeria
DXC Achieves Clean Sweep in NelsonHall's 2025 AI Infrastructure Management Rankings - Stock Titan
Intensity Therapeutics reports data from Invincible-4 study - TipRanks
Shelton-based biotech faces delisting threat from Nasdaq - Hartford Business Journal
Intensity Therapeutics Faces Nasdaq Delisting Notice - TipRanks
ibex to Showcase Industry’s Best AI-Powered CX Solutions at CCW Customer Contact Week 2025 - Stock Titan
New Cancer Drug Triples Survival Time for Hard-to-Treat Lung Cancer Patients in Phase 2 Trial - Stock Titan
Magnite Revolutionizes CTV Advertising with Exclusive AI Technology for Scene-by-Scene Ad Targeting - Stock Titan
Full Stock Market News from 2025-06-05 - Stock Titan
Cognizant Achieves 80% Migration Automation as Snowflake Names it Top Global Implementation Partner - Stock Titan
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
AECOM Sets July Payment Date for $0.26 Quarterly DividendKey Dates Inside - Stock Titan
IonQ Expands Quantum Computing Empire: 20+ Patents Added in Strategic Lightsynq Acquisition - Stock Titan
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - The Globe and Mail
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Harte Hanks Acquires Exclusive Rights to License ADS Data Direct's Premier Medical Ailment Database - Stock Titan
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - GuruFocus
Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - Morningstar
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Clean Tech Breakthrough: Zentek Partners With RSK to Launch Advanced Air Filters Across 20+ Global Markets - Stock Titan
Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga
Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com
Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus
Assembly's New META-Backed Marketing Tool Cuts Modeling Time 26%, Boosts ROI 13% With AI Innovation - Stock Titan
Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com
Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India
Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):